PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday
(Thomson Reuters ONE) -
Stem Cells Inc, (NASDAQ:STEM), developer of stem cell-based treatments for
spinal injury, is up for the second day in a row Friday in pre-market trading,
after it closed Thursday at $1.96, a 19% gain on the day. The gains came after
the company announced that it will be presenting data from its Phase I/II
clinical trial on Monday, Sept. 3 at the International Spinal Cord Society and
will hold a conference call the following day. Trading volume Thursday was three
times its 3-month average. The presentation will include interim data from the
study's first cohort, which has three partially paralyzed patients being treated
with STEM's proprietary HuCNS-SC cells. Researchers are looking for efficacy -
measured by improvement in motor function, sensation, and bladder control - and
safety in the first of three planned cohorts, each with more mild paralysis than
the previous. Share price is likely to remain strong on Friday and into the
meeting, as most analysts expect some positive results from the trial. If
Monday's data looks good for STEM, shares may climb higher on momentum, however,
negative results will have disastrous effects on the stock. STEM is up 140% in
2012.
Click here to see this article at PropThink.com.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more visit us at http://www.propthink.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1637958]
Unternehmensinformation / Kurzprofil:
Datum: 31.08.2012 - 15:28 Uhr
Sprache: Deutsch
News-ID 179494
Anzahl Zeichen: 2402
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: STEM Gains on Anticipation of Interim Trial Data to be Presented Monday"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
